Although these results may be confounded by more indolent myeloma disease biology allowing for more time between anti-BCMA therapies, these data suggest that using alternative therapies with different mechanisms of action may be a reasonable strategy to extend the duration of time between BCMA-targeted therapies. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.